| Similar Articles |
|---|
 |
The Motley Fool
October 10, 2007
Brian Lawler |
Bioenvision Demands a Recount Bioenvision decided to hold the polls open one more day, in hopes that some stockholders who hadn't yet participated would vote for their proposed acquisition by Genzyme.   |
The Motley Fool
May 30, 2007
Brian Lawler |
Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare. |
BusinessWeek
March 22, 2004
Gene G. Marcial |
Look Who May Be Courting Bioenvision Genzyme may be interested in Bioenvision as well. Why? In 2001, Bioenvision licensed to ILEX the right to co-develop and market in the U.S. and Canada its Clorfarabine, a drug for leukemia. Bioenvision still holds the rights outside North America. The company will soon file for Food & Drug Administration approval of Clorfarabine, which has a $1 billion market potential. |
BusinessWeek
June 4, 2007
Gene G. Marcial |
What Big Investors See In Bioenvision Bioenvision has attracted big investors. |
The Motley Fool
September 6, 2006
Brian Lawler |
AnorMED's Tumultuous Year A takeover attempt follows management shakeups at the biopharmaceutical firm. Investors, take note. |
BusinessWeek
May 2, 2005
Gene G. Marcial |
What Other Biotechs See In Bioenvision Bioenvision's childhood leukemia drug Clofarabine has received FDA approval and is expected to increase the profitability of the drug maker. |
The Motley Fool
October 29, 2007
Brian Lawler |
Genzyme Gets It Together Genzyme may not engender as much investor excitement as Carl-Icahn-acquisition-hyped biopharmas. But its diverse pipeline, and the strong performance it delivers quarter after quarter, deserve some investor attention. |
BusinessWeek
December 6, 2004
Gene G. Marcial |
Why There's New Life At Bioenvision Bioenvision's leading product, Clofarabine, for treating leukemia in children, may get Food & Drug Administration approval soon. Is the stock a good buy? |
The Motley Fool
January 9, 2008
Brian Lawler |
Tracking Genzyme The biopharma updates investors on what to expect for 2008. |
The Motley Fool
October 28, 2010
Brian Orelli |
This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
October 27, 2010
Selena Maranjian |
When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders. |
The Motley Fool
December 30, 2004
Charly Travers |
Genzyme Enters Cancer Arena The approval of a new drug is a long-term opportunity for the biotech giant. |
The Motley Fool
September 13, 2010
Brian Orelli |
When All Else Fails, Sell! Genzyme has no other choice. |
The Motley Fool
June 15, 2010
Ryan McBride |
Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week. |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
The Motley Fool
September 27, 2006
Brian Lawler |
Enormous Interest in AnorMED Genzyme and Millenium vie to purchase the Canadian biotech. Shares of AnorMED currently trade for more than $12 a share. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme. |
The Motley Fool
June 10, 2010
Brian Orelli |
Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday. |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
The Motley Fool
July 27, 2007
Brian Lawler |
Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too. |
The Motley Fool
July 12, 2006
Brian Lawler |
Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share. |
The Motley Fool
October 4, 2010
Brian Orelli |
That's No Way to Make Friends Sanofi goes hostile on Genzyme. |
The Motley Fool
November 24, 2010
Brian Orelli |
Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant. |
The Motley Fool
February 18, 2005
John Bluis |
Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises. |
The Motley Fool
April 26, 2007
Brian Lawler |
Genzyme Is Good The biopharma giant announced unexpectedly strong first-quarter results on the back of higher sales of recently launched compounds. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
March 2, 2004
David Nierengarten |
Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines. |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
August 30, 2010
Brian Orelli |
Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition? |
The Motley Fool
November 18, 2010
Brian Orelli |
Genzyme: Slimmed Down, Gussied Up But will anyone buy it? |
The Motley Fool
October 21, 2010
Brian Orelli |
Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track. |
BusinessWeek
February 9, 2004
Gene G. Marcial |
Envisioning A Buyout For Bioenvision What's George Soros buying? In biotech, he has accumulated 27% of Bioenvision, a little-known biopharma. Other investors: OrbiMed Advisors, with 8%, and Deutsche Bank, with nearly 5%. |
The Motley Fool
June 16, 2010
Ryan McBride |
Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
December 13, 2010
Brian Orelli |
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
The Motley Fool
September 11, 2010
Luke Timmerman |
Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce. |
The Motley Fool
September 23, 2010
Ryan McBride |
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault. |
Pharmaceutical Executive
July 3, 2007 |
Deals: Actavis Going Private? The board of the Icelandic generics maker holds out for a better offer.... Mylan Wins Merck Generics Unit... Genzyme to Acquire Bioenvision... etc. |
The Motley Fool
May 14, 2010
Ryan McBride |
Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back. |
The Motley Fool
July 18, 2005
Stephen D. Simpson |
Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky. |
The Motley Fool
November 14, 2007
Brian Lawler |
Genzyme Zigs, Shares Zag Genzyme gets downbeat news that will delay the launch of its lead drug, but shares rise. Investors, take note. |
The Motley Fool
April 16, 2004
Charly Travers |
Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out. |
The Motley Fool
July 7, 2010
Brian Orelli |
That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme. |
The Motley Fool
October 12, 2006
Brian Lawler |
Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading. |
The Motley Fool
February 4, 2008
Brian Lawler |
Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note. |
The Motley Fool
April 8, 2010
Brian Orelli |
Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult. |
The Motley Fool
November 29, 2010
Morgan Housel |
5 Stocks the Hedge Fund Greats Love Here's where you find cheap ideas. |
